Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 7/20 | 0.77 |
| ▸ | CDK1 | P06493 | 9/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.67 |
| ▸ | MGMT | P16455 | 8/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.67 |
| ▸ | CDK2 | P24941 | 8/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23511144 | 0.87 | PIN1 (1.00) | PIN1CDK1CCNB1MGMTCCNA2 | |
| SCHEMBL3297931 | 0.86 | PIN1 (1.00) | PIN1CDK1CCNB1MGMTCCNA2 | |
| 6-O-Benzylguanine SCHEMBL61740 | 0.81 | PIN1 (1.00) | PIN1CDK1CCNB1MGMTCCNA2 | |
| 6-O-Benzylguanine SCHEMBL31517079 | 0.81 | PIN1 (1.00) | PIN1CDK1CCNB1MGMTCCNA2 | |
| 6-O-Benzylguanine SCHEMBL4631744 | 0.80 | PIN1 (0.97) | PIN1CDK1CCNB1MGMTCCNA2 | |
| SCHEMBL29749175 | 0.80 | MGMT (0.81) | PIN1CDK1CCNB1MGMTCCNA2 | |
| SCHEMBL23124359 | 0.80 | MGMT (0.81) | PIN1CDK1CCNB1MGMTCCNA2 | |
| SCHEMBL21452794 | 0.78 | PIN1 (0.50) | PIN1CDK1CCNB1MGMTCCNA2 | |
| SCHEMBL3302852 | 0.78 | PIN1 (0.76) | PIN1CDK1CCNB1MGMTCCNA2 | |
| SCHEMBL3338895 | 0.78 | PIN1 (0.76) | PIN1CDK1CCNB1MGMTCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | disclosed |
| US-8791081-B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | LIU LILI | 2010-04-15 | — | — | US | disclosed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PIN1 2059/4885CDK1 566/4885CCNB1 569/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PIN1 1953/4885CDK1 566/4885CCNB1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.